L&K Bio Receives Import Approval for Spinal Surgery Equipment from Australian Therapeutic Goods Administration

[Asia Economy Reporter Hyungsoo Park] Spinal implant company L&K Biomed announced on the 6th that it has received import item approval from the Australian Therapeutic Goods Administration (TGA) for two types of spinal fixation devices.

L&K Biomed explained that it is entering the Australian market after completing the TGA certification process, which is responsible for the approval of pharmaceuticals and medical devices in Australia.

A company official stated, "These spinal fixation devices, applied to the cervical and lumbar regions, will undergo a review process for insurance reimbursement and will be clinically applied to Australian patients with spinal diseases starting from November." He added, "L&K Biomed's products will proudly compete in the Australian market, which is dominated by leading overseas companies, and contribute to improving the quality of life for Australian patients with spinal diseases."

The official continued, "The Australian spinal implant market has the second-highest insurance prices in the world after the United States, making it a highly profitable market," and explained, "L&K Biomed has additionally obtained certification for a competitive range of innovative products in the Australian market."

He further expressed expectations, saying, "Once the insurance reimbursement procedures are completed following the TGA approval, the Australian market will become an important growth driver in L&K Biomed's overseas strategy."

This content was produced with the assistance of AI translation services.